CervoMed (CRVO) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $2.24, -0.44% vs the prior close of $2.25.
- Volume 98.42K shares, 0.3x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
CRVO dips 0.4% to $2.24, a 52-week low. Closed at $2.24, -0.44% vs the prior close of $2.25. Day range $2.22–$2.30, opened at $2.25.
CRVO daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — CRVO dips 0.4% to $2.24, a 52-week low
- Closed at $2.24, -0.44% vs the prior close of $2.25. Day range $2.22–$2.30, opened at $2.25.
- Volume was 98.42K shares, 0.3x its 50-day average of 291.10K — lighter than usual.
- Price is -16.5% vs its 50-day average ($2.68) and -40.8% vs its 200-day average ($3.79).
- 52-week range $2.13–$10.00; today's close sits at 1% of that range, 77.6% below the 52-week high.
Oct 15, 2026 — CRVO dips 1.7% to $2.25, a 3-month low
- Closed at $2.25, -1.75% vs the prior close of $2.29. Day range $2.21–$2.31, opened at $2.26.
- Volume was 201.10K shares, 0.7x its 50-day average of 292.46K.
- Price is -16.5% vs its 50-day average ($2.69) and -41.0% vs its 200-day average ($3.81).
- 52-week range $2.13–$10.00; today's close sits at 2% of that range, 77.5% below the 52-week high.
Oct 14, 2026 — CRVO rises 0.9% to $2.29
- Closed at $2.29, +0.88% vs the prior close of $2.27. Day range $2.13–$2.41, opened at $2.22.
- Volume was 493.90K shares, 1.7x its 50-day average of 296.20K.
- Price is -15.3% vs its 50-day average ($2.70) and -40.4% vs its 200-day average ($3.84).
- 52-week range $2.13–$10.00; today's close sits at 2% of that range, 77.1% below the 52-week high.
- SEC filings that day: 8-K.
Oct 13, 2026 — CRVO slides 9.6% to $2.27, a 3-month low on 1.9x normal volume
- Closed at $2.27, -9.56% vs the prior close of $2.51. Day range $2.17–$2.53, opened at $2.50.
- Volume was 539.30K shares, 1.9x its 50-day average of 287.86K — unusually heavy trading.
- Price is -16.4% vs its 50-day average ($2.71) and -41.4% vs its 200-day average ($3.87).
- 52-week range $2.13–$10.00; today's close sits at 2% of that range, 77.3% below the 52-week high.
- That makes 3 straight losses.
- SEC filings that day: 8-K.
Oct 12, 2026 — CRVO slides 22.0% to $2.51 on 3.2x normal volume
- Closed at $2.51, -22.05% vs the prior close of $3.22. Day range $2.42–$2.79, opened at $2.75.
- Volume was 889.60K shares, 3.2x its 50-day average of 274.84K — unusually heavy trading.
- Price is -7.8% vs its 50-day average ($2.72) and -35.7% vs its 200-day average ($3.90).
- 52-week range $2.13–$10.00; today's close sits at 5% of that range, 74.9% below the 52-week high.
Oct 9, 2026 — CRVO dips 1.8% to $3.22
- Closed at $3.22, -1.83% vs the prior close of $3.28. Day range $3.17–$3.34, opened at $3.26.
- Volume was 231.60K shares, 0.8x its 50-day average of 273.95K.
- Price is +18.3% vs its 50-day average ($2.72) and -18.1% vs its 200-day average ($3.93).
- 52-week range $2.13–$10.00; today's close sits at 14% of that range, 67.8% below the 52-week high.
- SEC filings that day: 8-K.
Oct 8, 2026 — CRVO jumps 3.1% to $3.28
- Closed at $3.28, +3.14% vs the prior close of $3.18. Day range $3.13–$3.31, opened at $3.15.
- Volume was 340.00K shares, 1.2x its 50-day average of 274.43K.
- Price is +21.1% vs its 50-day average ($2.71) and -17.1% vs its 200-day average ($3.96).
- 52-week range $2.13–$10.00; today's close sits at 15% of that range, 67.2% below the 52-week high.
Oct 7, 2026 — CRVO slides 4.8% to $3.18
- Closed at $3.18, -4.79% vs the prior close of $3.34. Day range $3.13–$3.36, opened at $3.26.
- Volume was 308.80K shares, 1.1x its 50-day average of 276.49K.
- Price is +18.1% vs its 50-day average ($2.69) and -20.1% vs its 200-day average ($3.98).
- 52-week range $2.13–$10.00; today's close sits at 13% of that range, 68.2% below the 52-week high.
Oct 6, 2026 — CRVO rises 0.9% to $3.34, a 1-month high, 3 up days in a row
- Closed at $3.34, +0.91% vs the prior close of $3.31. Day range $3.11–$3.44, opened at $3.36.
- Volume was 469.80K shares, 1.7x its 50-day average of 273.19K.
- Price is +24.6% vs its 50-day average ($2.68) and -16.5% vs its 200-day average ($4.00).
- 52-week range $2.13–$10.00; today's close sits at 15% of that range, 66.6% below the 52-week high.
- That makes 3 straight gains.
Oct 5, 2026 — CRVO jumps 9.6% to $3.31, a 1-month high on 2.5x normal volume
- Closed at $3.31, +9.60% vs the prior close of $3.02. Day range $3.06–$3.35, opened at $3.13.
- Volume was 645.00K shares, 2.5x its 50-day average of 262.66K — unusually heavy trading.
- Price is +24.1% vs its 50-day average ($2.67) and -17.8% vs its 200-day average ($4.03).
- 52-week range $2.13–$10.00; today's close sits at 15% of that range, 66.9% below the 52-week high.
Oct 2, 2026 — CRVO jumps 3.1% to $3.02, a 1-month high
- Closed at $3.02, +3.07% vs the prior close of $2.93. Day range $2.88–$3.07, opened at $2.96.
- Volume was 241.80K shares, 0.9x its 50-day average of 264.57K.
- Price is +13.8% vs its 50-day average ($2.65) and -25.4% vs its 200-day average ($4.05).
- 52-week range $2.13–$10.00; today's close sits at 11% of that range, 69.8% below the 52-week high.
CRVO latest news & SEC filings
Every SEC filing by or about CRVO in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Oct 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Oct 9, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 28, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 7, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 7, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $0 (prior year $1.76M) (-100.0% vs Jun 30, 2025)
- Net income: -$6.57M (prior year -$6.26M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.64 (prior year -$0.70) (loss narrowed vs Jun 30, 2025)
Aug 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Jul 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Jul 10, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Things to know before you trade CRVO
- Last results release: Aug 10, 2026 (8-K Item 2.02). Previous ones: May 18, 2026, Mar 17, 2026, Nov 10, 2025. Based on that rhythm, the next report is likely around Nov 9, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.16% (largest 22.0%). That is a volatile stock.
- Liquidity: about 315.87K shares (≈$707.55K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $2.24 vs a range of $2.13–$10.00 (1% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 25 open-market buys, 0 sales; latest: Joshua S Boger bought 955,414 shares on Jun 11, 2026.
- Latest filings: 8-K Oct 14, 2026; 8-K Oct 13, 2026; 8-K Oct 9, 2026.
- Share count: 15.12M shares outstanding (Aug 6, 2026), +63.4% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
CRVO market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 2.25 | 2.30 | 2.22 | 2.24 | 98.42K |
| Oct 15, 2026 | 2.26 | 2.31 | 2.21 | 2.25 | 201.10K |
| Oct 14, 2026 | 2.22 | 2.41 | 2.13 | 2.29 | 493.90K |
| Oct 13, 2026 | 2.50 | 2.53 | 2.17 | 2.27 | 539.30K |
| Oct 12, 2026 | 2.75 | 2.79 | 2.42 | 2.51 | 889.60K |
| Oct 9, 2026 | 3.26 | 3.34 | 3.17 | 3.22 | 231.60K |
| Oct 8, 2026 | 3.15 | 3.31 | 3.13 | 3.28 | 340.00K |
| Oct 7, 2026 | 3.26 | 3.36 | 3.13 | 3.18 | 308.80K |
| Oct 6, 2026 | 3.36 | 3.44 | 3.11 | 3.34 | 469.80K |
| Oct 5, 2026 | 3.13 | 3.35 | 3.06 | 3.31 | 645.00K |
| Oct 2, 2026 | 2.96 | 3.07 | 2.88 | 3.02 | 241.80K |
| Oct 1, 2026 | 2.98 | 2.98 | 2.86 | 2.93 | 172.90K |
| Sep 30, 2026 | 2.91 | 3.05 | 2.75 | 2.97 | 375.50K |
| Sep 29, 2026 | 2.70 | 2.92 | 2.67 | 2.88 | 449.00K |
| Sep 28, 2026 | 2.55 | 2.68 | 2.54 | 2.67 | 171.10K |
| Sep 25, 2026 | 2.52 | 2.63 | 2.52 | 2.54 | 106.10K |
| Sep 24, 2026 | 2.46 | 2.53 | 2.43 | 2.52 | 90.60K |
| Sep 23, 2026 | 2.59 | 2.60 | 2.50 | 2.51 | 123.50K |
| Sep 22, 2026 | 2.43 | 2.61 | 2.42 | 2.53 | 260.60K |
| Sep 21, 2026 | 2.47 | 2.49 | 2.41 | 2.41 | 108.80K |
About CervoMed
CervoMed (CRVO) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in BOSTON, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1053691.
CRVO board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| John J Alam | CEO & President | Jun 10, 2026 |
| Joshua S Boger | Director | Jun 15, 2026 |
| Sylvie Gregoire | Director | Jun 10, 2026 |
| Jane H Hollingsworth | Director | Jun 10, 2026 |
| Jeffrey V. Poulton | Director | Jun 10, 2026 |
| David Quigley | Director | Jun 10, 2026 |
| Marwan Sabbagh | Director | Jun 10, 2026 |
| Frank Zavrl | Director | Jun 10, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| John J Alam | CEO & President | Jun 10, 2026 |
| Kelly Blackburn | EVP, Clinical Development | Feb 13, 2026 |
| Rosch Mark De | EVP, RA and GA and PgM | Feb 13, 2026 |
| William Robert Elder | CFO, GC & Secretary | Feb 13, 2026 |
| Matthew Winton | Chief Commercial and Business | Feb 13, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 11, 2026 | Joshua S Boger | Buy | 955,414 | $3.14 |
| Jun 11, 2026 | Joshua S Boger | Buy | 955,414 | $3.14 |
| Jun 11, 2026 | Joshua S Boger | Buy | 955,414 | $3.14 |
| Jun 11, 2026 | Joshua S Boger | Buy | 955,414 | $3.14 |
| Nov 18, 2025 | William Robert Elder | Buy | 2,500 | $8.32 |
| Nov 18, 2025 | William Robert Elder | Buy | 2,500 | $8.32 |
| Nov 18, 2025 | William Robert Elder | Buy | 2,500 | $8.32 |
| Nov 18, 2025 | William Robert Elder | Buy | 2,500 | $8.32 |
| Nov 18, 2025 | Matthew Winton | Buy | 1,500 | $7.95 |
| Nov 18, 2025 | Matthew Winton | Buy | 1,500 | $7.95 |
| Nov 18, 2025 | Matthew Winton | Buy | 1,500 | $7.95 |
| Nov 18, 2025 | Matthew Winton | Buy | 1,500 | $7.95 |
| Nov 17, 2025 | Sylvie Gregoire | Buy | 10,793 | $8.46 |
| Nov 17, 2025 | Sylvie Gregoire | Buy | 10,807 | $8.46 |
| Nov 17, 2025 | Sylvie Gregoire | Buy | 10,793 | $8.46 |
CRVO financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $4.01M | $-26.97M | — | $-23.45M |
| Dec 31, 2024 | $9.74M | $-16.29M | — | $-16.53M |
| Dec 31, 2023 | $7.14M | $-2.17M | — | $-7.45M |
| Dec 31, 2022 | $0 | $-5.80M | 2,038,891.00 | $-2.57M |
| Dec 31, 2021 | — | $-24.10M | 1,946,859.00 | $-14.50M |
Latest balance sheet: total assets $25.99M, total liabilities $3.03M, cash $22.46M (as of Jun 30, 2026).
CRVO earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 10, 2026 | 8-K Item 2.02 (results) | $2.86 |
| May 18, 2026 | 8-K Item 2.02 (results) | $3.04 |
| Mar 17, 2026 | 8-K Item 2.02 (results) | $4.53 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $6.90 |
| Aug 11, 2025 | 8-K Item 2.02 (results) | $9.50 |
| May 12, 2025 | 8-K Item 2.02 (results) | $9.10 |
| Mar 18, 2025 | 8-K Item 2.02 (results) | $9.34 |
| Nov 13, 2024 | 8-K Item 2.02 (results) | $11.22 |
| Aug 15, 2024 | 8-K Item 2.02 (results) | — |
| May 15, 2024 | 8-K Item 2.02 (results) | — |
| Apr 5, 2024 | 8-K Item 2.02 (results) | — |
| Nov 13, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on CRVO
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.